ATE540952T1 - Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese - Google Patents

Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese

Info

Publication number
ATE540952T1
ATE540952T1 AT06779900T AT06779900T ATE540952T1 AT E540952 T1 ATE540952 T1 AT E540952T1 AT 06779900 T AT06779900 T AT 06779900T AT 06779900 T AT06779900 T AT 06779900T AT E540952 T1 ATE540952 T1 AT E540952T1
Authority
AT
Austria
Prior art keywords
pyrroloä2
düpyrimidine
synthesis
derivatives
intermediate products
Prior art date
Application number
AT06779900T
Other languages
English (en)
Inventor
Sally Gut Ruggeri
Joel Michael Hawkins
Teresa Margaret Makowski
Jennifer Lea Rutherford
Frank John Urban
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE540952T1 publication Critical patent/ATE540952T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT06779900T 2005-07-29 2006-07-17 Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese ATE540952T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70401105P 2005-07-29 2005-07-29
PCT/IB2006/002048 WO2007012953A2 (en) 2005-07-29 2006-07-17 Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis

Publications (1)

Publication Number Publication Date
ATE540952T1 true ATE540952T1 (de) 2012-01-15

Family

ID=36950230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779900T ATE540952T1 (de) 2005-07-29 2006-07-17 Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese

Country Status (24)

Country Link
US (2) US8232394B2 (de)
EP (1) EP1913000B1 (de)
JP (1) JP4052523B2 (de)
KR (1) KR100987870B1 (de)
CN (1) CN101233138A (de)
AR (1) AR056004A1 (de)
AT (1) ATE540952T1 (de)
AU (1) AU2006273762A1 (de)
BR (1) BRPI0613876A2 (de)
CA (1) CA2614907C (de)
CY (1) CY1112319T1 (de)
DK (1) DK1913000T3 (de)
ES (1) ES2377771T3 (de)
IL (1) IL188372A0 (de)
MX (1) MX2008001334A (de)
NZ (1) NZ565363A (de)
PL (1) PL1913000T3 (de)
PT (1) PT1913000E (de)
RU (1) RU2384583C2 (de)
SG (1) SG170783A1 (de)
SI (1) SI1913000T1 (de)
TW (1) TWI319402B (de)
WO (1) WO2007012953A2 (de)
ZA (1) ZA200800284B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007839A1 (en) 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
MX2012002641A (es) * 2009-09-10 2012-03-14 Hoffmann La Roche Inhibidores de cinasa janus (jak).
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
CA2782720A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
AU2011213198B2 (en) 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
CN103459394B (zh) 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
EP2788000B1 (de) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidine als januskinaseinhibitoren
WO2013090490A1 (en) * 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
CN104619693B (zh) * 2012-07-17 2019-08-13 葛兰素史克知识产权第二有限公司 作为选择性雄激素受体调节剂的吲哚腈类
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
CN102875555A (zh) * 2012-09-27 2013-01-16 同济大学 一种JAK抑制剂Tofacitinib的合成方法
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
EP2935216B1 (de) 2012-12-17 2018-06-27 Sun Pharmaceutical Industries Limited Verfahren zur herstellung von tofacitinib und zwischenprodukten davon
EP2938616A4 (de) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd Verarbeitungsverfahren zur herstellung von tofacitinib und zwischenprodukten davon
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
EA027879B1 (ru) * 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
CN104292231B (zh) * 2013-09-17 2016-11-30 广东东阳光药业有限公司 一种枸橼酸托法替尼的制备方法
CN105873931B (zh) * 2013-10-08 2018-10-16 广东东阳光药业有限公司 托法替布柠檬酸盐
CN103819474A (zh) * 2013-11-04 2014-05-28 湖南华腾制药有限公司 一种托法替尼的制备方法
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
ES2865058T3 (es) 2013-12-09 2021-10-14 Unichem Lab Ltd Un proceso mejorado para la preparación de (3R,4R)-(1-bencil-4-metilpiperidin-3-il)-metilamina
CN104774206A (zh) * 2014-01-14 2015-07-15 江苏柯菲平医药股份有限公司 制备枸橼酸托伐替尼晶型a的新方法
CN103755624B (zh) * 2014-01-20 2018-10-09 上海博氏医药科技有限公司 一种哌啶衍生物的合成方法
CN105085527A (zh) * 2014-05-20 2015-11-25 南京海纳医药科技有限公司 高效合成托法替尼的方法
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
MX2017002775A (es) * 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
CN104530053A (zh) * 2014-12-08 2015-04-22 合肥远志医药科技开发有限公司 一种药用晶型枸橼酸托法替尼的制备方法
CN104530055A (zh) * 2014-12-23 2015-04-22 南京艾德凯腾生物医药有限责任公司 枸橼酸托法替布的制备方法
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
CN104710346B (zh) * 2015-02-15 2017-04-12 江苏苏利精细化工股份有限公司 一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法
WO2016132341A1 (en) * 2015-02-20 2016-08-25 Sun Pharmaceutical Industries Limited A process for the preparation of tofacitinib citrate
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
CN104860872A (zh) * 2015-03-27 2015-08-26 天津药物研究院有限公司 一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法
EP3078665A1 (de) 2015-04-10 2016-10-12 OLON S.p.A. Effizientes verfahren zur herstellung von tofacitinib-citrat
CN104788461A (zh) * 2015-04-30 2015-07-22 南京臣功制药股份有限公司 一种适合枸橼酸托法替尼工业化的生产方法
CA2984183C (en) 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
CN104987339A (zh) * 2015-07-29 2015-10-21 张燕梅 一种枸橼酸托法替布的合成方法
RU2699034C1 (ru) 2016-02-16 2019-09-03 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Способ получения соединений 7H-пирроло[2,3-d]пиримидина
CN105732641A (zh) * 2016-03-28 2016-07-06 南通常佑药业科技有限公司 一种JAKs抑制剂药物托法替尼的制备方法
CN105884781B (zh) * 2016-04-18 2018-04-20 山东罗欣药业集团股份有限公司 一种枸橼酸托法替布的制备方法
CN106146517B (zh) * 2016-06-20 2018-08-28 山东大学 一种枸橼酸托法替尼的合成方法
CN106188064A (zh) * 2016-07-07 2016-12-07 国药集团容生制药有限公司 一种N‑甲基‑N‑((3R，4R)‑4‑甲基吡啶‑3‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑4‑胺的制备方法
CN105949204A (zh) * 2016-07-25 2016-09-21 国药集团容生制药有限公司 一种N-((3R，4R)-1-苄基-4-甲基吡啶-3-基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺的制备方法
SG10202106949XA (en) 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
EP3421455B1 (de) 2017-06-29 2019-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Verbessertes verfahren zur herstellung von chiralen 3-amino-piperidinen, nützliche zwischenprodukte zur herstellung von tofacitinib
CN109293682A (zh) * 2017-07-25 2019-02-01 重庆医药工业研究院有限责任公司 一种托法替布杂质及其制备方法
CN107698595A (zh) * 2017-09-23 2018-02-16 江苏正大清江制药有限公司 一种枸橼酸托法替布有关物质的制备方法
CN107793418B (zh) * 2017-10-24 2020-08-04 扬子江药业集团有限公司 一种枸橼酸托法替布的工业化生产方法
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
CN108822112B (zh) * 2018-08-13 2019-12-20 山东罗欣药业集团恒欣药业有限公司 一种托法替尼化合物的制备方法
CN109608468B (zh) * 2018-12-29 2020-09-29 成都倍特药业股份有限公司 一种枸橼酸托法替布杂质及其合成方法和用途
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
CN109503462B (zh) * 2019-01-21 2022-03-25 内蒙古京东药业有限公司 托法替布中间体(3r，4r)-n，4-二甲基-1-苄基-3-哌啶胺的合成方法
CN109761884B (zh) * 2019-01-30 2020-03-31 湖北扬信医药科技有限公司 一种手性胺b的制备方法及其应用
CA3132109A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
EP3946606B1 (de) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclische jak-inhibitoren und verwendungen davon
KR102890724B1 (ko) * 2019-04-05 2025-11-25 주식회사유한양행 (3r,4r)-1-벤질-n,4-디메틸피페리딘-3-아민 또는 이의 염의 제조방법 및 이를 이용한 토파시티닙의 제조방법
KR102897231B1 (ko) 2019-10-31 2025-12-05 아르티 인더스트리스 리미티드 토파시티닙 및 그 중간체의 제조방법
CN110724146B (zh) * 2019-11-04 2022-03-11 四川大学 一种枸橼酸托法替布的制备方法
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CN112159410B (zh) * 2020-09-30 2025-10-17 天地恒一制药股份有限公司 一种高纯度枸橼酸托法替布的制备方法
CN114685510A (zh) * 2020-12-25 2022-07-01 上海科胜药物研发有限公司 一种托法替布中间体及其制备方法
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途
CN112679508B (zh) * 2021-03-09 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 一种托法替布中间体的制备方法
CN113248509B (zh) * 2021-05-17 2022-10-04 上海中西三维药业有限公司 一种枸橼酸托法替布中间体的制备方法
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
CA3226714A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
CN113735860A (zh) * 2021-08-26 2021-12-03 安徽鼎旺医药有限公司 一种枸橼酸托法替布的合成方法
CN114685515A (zh) * 2022-03-15 2022-07-01 上海蓝乐鸟实业有限公司 一种托法替尼的制备方法
CN114835714A (zh) * 2022-04-01 2022-08-02 上海蓝乐鸟实业有限公司 一种托法替尼的制备方法
CN118056828A (zh) * 2022-11-18 2024-05-21 江苏晶立信医药科技有限公司 一种托法替布关键中间体的制备方法
CN117185884A (zh) * 2023-09-08 2023-12-08 四川大学 一种(r)-4-取代六氢嘧啶化合物的合成方法
CN117247388A (zh) * 2023-09-18 2023-12-19 天地恒一制药股份有限公司 托法替布及其中间体的制备方法和系统
CN118290348A (zh) * 2024-03-22 2024-07-05 诚达药业股份有限公司 一种4-氯吡咯并嘧啶类化合物或其衍生物的合成方法
WO2026153364A1 (zh) * 2025-01-14 2026-07-23 明慧医药（杭州）有限公司 一种jak抑制剂化合物的制备方法、晶型，及其中间体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0710877A (ja) * 1993-06-24 1995-01-13 Teijin Ltd ４―ヘテロアリサイクリック―ピロロ［２，３―ｄ］ピリミジン
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
HRP20031049A2 (en) 2001-06-23 2004-06-30 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
PY0228255A (es) 2001-12-06 2004-06-01 Pfizer Prod Inc Compuestos cristalinos novedosos
US20040012627A1 (en) 2002-07-17 2004-01-22 Sany Zakharia Configurable browser for adapting content to diverse display types
WO2004021979A2 (en) * 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
RS20050380A (sr) 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
EP1620109A2 (de) * 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhbitor phosphonat konjugate

Also Published As

Publication number Publication date
WO2007012953A3 (en) 2007-05-18
JP2007039455A (ja) 2007-02-15
CA2614907A1 (en) 2007-02-01
IL188372A0 (en) 2008-04-13
TW200745119A (en) 2007-12-16
KR100987870B1 (ko) 2010-10-13
TWI319402B (en) 2010-01-11
CN101233138A (zh) 2008-07-30
US20110288297A1 (en) 2011-11-24
US20120259115A1 (en) 2012-10-11
ES2377771T3 (es) 2012-03-30
BRPI0613876A2 (pt) 2011-02-15
KR20080031338A (ko) 2008-04-08
JP4052523B2 (ja) 2008-02-27
AU2006273762A1 (en) 2007-02-01
RU2384583C2 (ru) 2010-03-20
WO2007012953A2 (en) 2007-02-01
NZ565363A (en) 2010-03-26
US8232394B2 (en) 2012-07-31
EP1913000A2 (de) 2008-04-23
RU2008103279A (ru) 2009-08-10
US8309716B2 (en) 2012-11-13
PT1913000E (pt) 2012-02-28
CA2614907C (en) 2012-02-28
MX2008001334A (es) 2008-03-24
SG170783A1 (en) 2011-05-30
AR056004A1 (es) 2007-09-12
DK1913000T3 (da) 2012-03-12
ZA200800284B (en) 2008-12-31
PL1913000T3 (pl) 2012-05-31
CY1112319T1 (el) 2015-12-09
SI1913000T1 (sl) 2012-02-29
EP1913000B1 (de) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE486076T1 (de) 6-carboxy-normorphinan-derivate, ihre synthese und verwendung
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
SI1913001T1 (sl) (r)-n-metilnaltrekson, postopki za njega sintezo in njega farmacevtsko uporabo
DK1913000T3 (da) Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese
EP1943338A4 (de) Zellfreie synthese membrangebundener polypeptide
ATE550315T1 (de) Pestizid-bi-phenyl-amidin-derivate
DK1957073T3 (da) Lægemiddel
IL188896A0 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DE602006010343D1 (de) Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
PT1876916E (pt) Produto
EP1984313A4 (de) Molekularsieb-ssz-74-stoffzusammensetzung und synthese davon
DE602006014973D1 (de) Neuartige cercosporamidderivate
EP1849270A4 (de) Interworking
EP1950265A4 (de) Wärmespeichermikrokapsel, wärmespeichermikrokapseldispersion und verfestigtes produkt der wärmespeichermikrokapsel
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
EP1753299A4 (de) Nahrungsmittelprodukt
EP1947177A4 (de) Neue endoribonuklease
ATE541837T1 (de) Oxaphenanthren-derivate
ATE374761T1 (de) Syntheseverfahren und benzoxathiepinzwischenprodukte